Management of newly diagnosed high‐risk and intermediate‐risk follicular lymphoma with 90Y ibritumomab tiuxetan in a phase II study
Sign Up to like & getrecommendations! Published in 2018 at "Hematological Oncology"
DOI: 10.1002/hon.2513
Abstract: Five‐year overall survival for high‐risk Follicular Lymphoma International Prognostic Index follicular lymphoma is only approximately 50% compared with 90% for low risk. To evaluate an approach to improve upon this poor outcome, we completed an… read more here.
Keywords: risk; immunotherapy; risk follicular; high risk ... See more keywords